Tuesday, April 16th, 2024Market indices fluctuated today. The S&P 500 and Nasdaq were in-line throughout the day, right around breakeven (-0.21% and -0.12%, respectively). The Dow stayed in the green for all but a few minutes on the session, finishing +0.17%. The Russell 2000 only spent a moment out of negative territory today, reaching the closing bell at -0.42%. Fed Chair Jerome Powell’s comments today solidified that monetary policy is seriously considering delaying its first rate cut until economic repo ...

LAS VEGAS, NEVADA - JANUARY 10: An Abbott logo is displayed at the company's booth during CES 2024 ... [+] at the Las Vegas Convention Center on January 10, 2024 in Las Vegas, Nevada. (Photo by Ethan Miller/Getty Images)Getty ImagesAbbott (NYSE: ABT) will report its Q1 2024 results on Wednesday, April 17. We expect the company to post revenue of $9.9 billion and earnings of $0.95 on a per share and adjusted basis, aligning with the street expectations. We expect a low double-digit uptick in sales for the co ...

With the Q1 earnings season underway, there will be a microscope on companies that can continue to show improvements in their outlook amid an uptick in inflation.That said, several top-rated Zacks stocks are standing out before their quarterly report next week, and here are three to consider.  Interactive Brokers (IBKR) First quarter results from Interactive Brokers on Tuesday, April 16 are expected to reflect considerable growth in the global electronic security exchange providers' top and bottom lines. Qu ...

Abbott Laboratories (ABT) is slated to report its first-quarter 2024 results on Apr 17, before market open.The company posted adjusted earnings per share (EPS) of $1.19 in the last reported quarter, which matched the Zacks Consensus Estimate. In the trailing four quarters, its earnings exceeded the Zacks Consensus Estimate on three occasions and came in line on one occasion, the average beat being 3.15%.Let's see how things have shaped up prior to this announcement.Factors at PlayEstablished Pharmaceuticals ...

With rising concerns in the market potentially forcing a strategic shift, investors may want to consider healthcare stocks. No matter what happens, people need access to health-related products and services. It’s one of the essentials of life, which makes the industry such a politically sensitive matter.Besides the critical need, another element that helps bolster the case for healthcare stocks is the underlying diversity. Yes, the sector centers on the pharmaceutical innovation space. However, the arena co ...

The lack of demand for Abbott’s (ABT) COVID-19 tests has been limiting overall growth. Foreign exchange fluctuations continue to hamper growth as well. The stock carries a Zacks Rank #4 (Sell) currently.Following the official ending of the public health emergency in 2023, Abbott has been experiencing a continuous decline in COVID testing-related demand. In Rapid Diagnostics, sales decreased 49.2% in the fourth quarter of 2023, excluding the effect of foreign exchange, due to the lower demand for COVID-19 te ...

Abbott Laboratories, Inc. (ABT) recently secured the FDA’s approval for the TriClip transcatheter edge-to-edge repair (TEER) system, which is specifically designed for the treatment of tricuspid regurgitation (TR) or a leaky tricuspid valve. This approval follows the recent recommendation of the Circulatory System Devices Panel of the Medical Devices Advisory Committee for the FDA, whose vote confirmed 13 to 1, with 0 abstentions, that the benefits of TriClip outweighed the risks.The approval helps address ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Abbott (ABT) .Abbott currently has an average brokerage recommendation (AB ...

Abbott Laboratories, Inc. (ABT) recently announced the receipt of the FDA approval for the i-STAT TBI (traumatic brain injury) cartridge.  The test runs on Abbott's portable i-STAT Alinity instrument, which uses whole blood to help assess patients with a suspected mild traumatic brain injury (mTBI) or concussion. The test delivers lab-quality results in 15 minutes.The latest development expands Abbott's TBI test offering, fortifying its Diagnostics business.More on for i-STAT TBI cartridgeAbbott's i-STAT TB ...

The latest trading session saw Abbott (ABT) ending at $112.09, denoting a -1.38% adjustment from its last day's close. This change lagged the S&P 500's 0.2% loss on the day. Elsewhere, the Dow saw a downswing of 0.6%, while the tech-heavy Nasdaq appreciated by 0.11%.Shares of the maker of infant formula, medical devices and drugs witnessed a loss of 4.18% over the previous month, trailing the performance of the Medical sector with its gain of 2.21% and the S&P 500's gain of 3.32%.Market participants will be ...